← Back to Search

Other

MET097 for Obesity

Anaheim, CA
Phase 1 & 2
Waitlist Available
Research Sponsored by Metsera
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
At least 18 years of age but not older than 70 years of age
Be older than 18 years old
Must not have
Diagnosis of diabetes (type 1 or type 2)
Obesity induced by endocrinologic disorders (e.g., Cushing's syndrome) or diagnosed monogenetic or syndromic forms of obesity (e.g., Melanocortin 4 Receptor deficiency or Prader-Willi Syndrome)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years

Summary

This trial aims to test the safety, effectiveness, and how the body processes a drug called MET097 when given as a once-weekly injection to overweight or obese adults. The trial will be done in

See full description
Who is the study for?
This trial is for healthy adults who are overweight or obese. Participants will receive weekly injections and may be eligible if they meet specific weight criteria, but can't join if they have other significant health issues or are taking certain medications that could interfere with the study.Check my eligibility
What is being tested?
The study tests MET097, a new drug given as a once-weekly subcutaneous injection to see if it's safe and effective for weight loss. It has three parts: single doses (Part A), multiple doses (Part B), and longer-term dosing with potential monthly options (Part C). Some participants will get a placebo instead of the actual drug.See study design
What are the potential side effects?
Possible side effects include reactions at the injection site, gastrointestinal symptoms like nausea or diarrhea, headaches, fatigue, and potentially allergic responses. The full range of side effects isn't known yet since this is an early-stage trial.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 18 and 70 years old.
 show original

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have been diagnosed with diabetes.
 show original
Select...
I have obesity due to a hormonal disorder or a genetic condition.
 show original
Select...
I or my family have a history of medullary thyroid cancer or multiple endocrine neoplasia.
 show original
Select...
I am not pregnant or breastfeeding.
 show original

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: (Part C) MET097Experimental Treatment1 Intervention
Once-weekly subcutaneous injection of MET097 for 13 weeks
Group II: (Part C) PlaceboPlacebo Group1 Intervention
Once-weekly subcutaneous injection of Placebo for 13 weeks

Find a Location

Closest Location:Research Site MET097 23-101-001· Overland Park, KS· 627 miles
Image of Research Site MET097 23-101-001 in Overland Park, United States.Image of Research Site MET097 23-101-001 in Overland Park, United States.Image of Research Site MET097 23-101-001 in Overland Park, United States.

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

MetseraLead Sponsor
1 Previous Clinical Trials
225 Total Patients Enrolled
1 Trials studying Obesity
225 Patients Enrolled for Obesity
~137 spots leftby Mar 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top